High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
复制标题
DOI：
10.1186/s12885-015-1840-6
复制
发表时间：
2015-11-02
期刊：
影响因子：
3.8
通讯作者：
Wang, Jianping
中科院分区：
文献类型：
--
作者：
Deng, Yanhong;Cai, Yue;Wang, Jianping
背景：SLFN11被报道为DNA损伤药物的预测标记物。本研究旨在探讨SLFN11在结直肠癌中的表达与奥沙利铂辅助化疗敏感性的关系。方法：用抗SLFN11抗体对连续261例接受奥沙利铂辅助化疗的结直肠癌患者的组织芯片进行染色。染色分为高表达和低表达。结果：SLFN11高表达占16.9%，KRAS外显子2突变占32.2%。SLFN11在高、中分化肿瘤中的表达高于低分化肿瘤(21%vs4.9%，P=0.003)和II期肿瘤(26.1%vs11.4%，p=0.006)。153例KRAS外显子2野生型结直肠癌患者中有23例SLFN11高表达，23例患者无死亡事件，直至最后一次随访。这些患者的总生存率(OS)显著高于SLFN11低表达肿瘤(100%vs78.2%，LOG等级P=0.048)。但在外显子2突变的结直肠癌患者中，SLFN11高表达和低表达患者的OS差异无统计学意义(LOG等级P=0.709)。结论：SLFN11表达预示着接受奥沙利铂辅助化疗的KRAS外显子2野生型结直肠癌患者有较好的生存率。
Background: SLFN11 was reported to be a predictive marker for DNA damage drugs. The study was to investigate whether SLFN11 expression is related to sensitivity to adjuvant oxaliplatin-based treatment in colorectal cancer.Methods: A tissue microarray, made with specimens from consecutive 261 patients who received oxaliplatin based adjuvant chemotherapy, was stained with anti-SLFN11 antibody. The staining was dichotomized as high or low expression. SLFN11 expression was correlated to clinicopathological factors, KRAS exon 2 mutation and survival.Results: SLFN11 high expression was found in 16.9 % of patients, and KRAS exon 2 mutation was detected in 32.2 % of patients. SLFN11 was expressed more common in well/moderate differentiation tumors(comparing to poor differentiation ones, 21 % v 4.9 %, P = 0.003) and stage II tumors(comparing to stage III tumors, 26.1 % v 11.4 %, p = 0.006). 23 out of 153 patients with KRAS exon 2 wild-type CRC had SLFN11 high expression, no death events was recorded in the 23 patients until last follow up. These patients had significantly better overall survival (OS) than those with SLFN11 low expression tumors (100 % vs 78.2 %, log rank P = 0.048). However, among patients with KRAS exon 2 mutant tumors, OS did not significantly differ between those with SLFN11 high and SLFN11 low tumors (Log rank P = 0.709).Conclusions: SLFN11 expression predicts good better survival in colorectal cancer patients with KRAS exon 2 wild type who have received oxaliplatin based adjuvant chemotherapy.